Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CIITA
REST API REST API
Homo sapiens
CIITA is differentially expressed in 254 experiments: 135 organism parts: lung, bone marrow, ... (133 more);, 228 disease states: normal, control, ... (226 more);, 102 cell types 324 cell lines 27 compound treatments and 80 other conditions.
Synonyms C2TA, NLRA, MHC2TA
Orthologs CIITA (Gallus gallus)   ciita (Danio rerio)   CIITA (Bos taurus)   Ciita (Mus musculus)   Ciita (Rattus norvegicus)   ciita (Xenopus laevis)   CIITA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term response to antibiotic, negative regulation of transcription, DNA-dependent, protein binding, regulation of transcription, DNA-dependent, cytokine-mediated signaling pathway, ATP binding, positive regulation of transcription from RNA polymerase II promoter, transcription coactivator activity, nucleus, nucleotide binding, immune response, protein C-terminus binding, nucleoplasm, negative regulation of transcription from RNA polymerase II promoter, positive regulation of transcription, DNA-dependent, response to interferon-gamma, negative regulation of collagen biosynthetic process, positive regulation of MHC class II biosynthetic process, protein complex binding, activating transcription factor binding, interferon-gamma-mediated signaling pathway, positive regulation of MHC class I biosynthetic process, transcription regulatory region DNA binding
InterPro Term NACHT_NTPase, Leu-rich_rpt_RNase_inh_sub-typ, Leu-rich_rpt, MHC_II_transact
UniProt Accession P33076, A0N0N9, E9PFE0, F2Z2G8, F5H2J4
Gene-Disease Assocation BARE LYMPHOCYTE SYNDROME, TYPE II, MULTIPLE SCLEROSIS, SUSCEPTIBILITY TO; MS, RHEUMATOID ARTHRITIS; RA
Search EB-eye ENSG00000179583
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-2450, E-MTAB-62, ... (31 experiments)

Factor Value U/D Experiments
MCF-7
1
3
E-GEOD-20081, E-GEOD-5823, E-GEOD-3529, E-GEOD-19639
HL-60
2
E-GEOD-24147, E-GEOD-5258
RPMI 8226
1
E-MEXP-921
HEK293
1
E-MTAB-62
SR
1
E-MTAB-37
BC-1
1
E-GEOD-2149
318 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-3920, E-MEXP-120, E-MEXP-66, E-GEOD-4219, ... (47 experiments)

Factor Value U/D Experiments
testis - germ cell
2
E-AFMX-5, E-TABM-145
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
CD34+
2
E-TABM-145, E-AFMX-5
CD34+CD38-/lowCD19+ cell
1
E-MEXP-1403
naive T cell
1
E-GEOD-1460
primary CD34- mesenchymal stem cell
1
E-MEXP-66
96 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-1577, E-MEXP-1121, E-MTAB-62, E-GEOD-5418, ... (58 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
3
E-MTAB-37, E-MEXP-231, E-MTAB-62
gastric carcinoma
2
E-MTAB-37, E-GEOD-15460
AIDS-KS, HIV+, nodular (late) stage
2
2
E-MTAB-62, E-MEXP-66
Emery-Dreifuss muscular dystrophy
2
E-MTAB-62, E-GEOD-3307
colon carcinoma
2
E-MTAB-37, E-MTAB-62
glioblastoma
2
E-GEOD-4290, E-GEOD-4412
222 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5824, E-TABM-868, E-GEOD-5099, E-GEOD-15811, ... (19 experiments)

Factor Value U/D Experiments
none
4
5
E-MEXP-1230, E-MEXP-1958, E-GEOD-5824, E-GEOD-412, E-GEOD-2803, ... (9 experiments)
actinomycin D
1
E-GEOD-6400
hydrogen peroxide
1
E-GEOD-5339
BCR/ABL1
1
1
E-GEOD-15811
ZMYM2/FGFR1
1
E-GEOD-15811
5-aza-2'-deoxycytidine
3
1
E-MEXP-1269
21 more value(s).


Age at diagnosis

studied in E-GEOD-4922

Factor Value U/D Experiments
84 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, E-GEOD-2171, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-1140, E-MEXP-1251, E-GEOD-21374, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-2666, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-21138, E-GEOD-21887, E-GEOD-1751 ... (5 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-563

Genotype
studied in E-GEOD-17476, E-GEOD-21750, E-GEOD-22593, E-TABM-321, E-TABM-43, ... (9 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-12773, E-TABM-127, E-GEOD-20540, E-MEXP-1446, ... (7 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-GEOD-1926, E-MEXP-2069, ... (27 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-MEXP-1403

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

Qpcr egfr dct
studied in E-GEOD-5851

RNAi
studied in E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70

Sex
studied in E-GEOD-19743, E-GEOD-19069, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-TABM-43

Tumor size
studied in E-GEOD-3494

Processing time: 0.343 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM